NCT00056537 - ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions

Non-Small-Cell Lung CarcinomaRenal Cell CarcinomaPancreatic Cancer

Interventions

DRUG

ABR-217620

Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles

Trial Locations (3)

19111

Fox Chase Cancer Center, Philadelphia

Unknown

Det Norske Radiumhospitalet, Oslo

M20 4BX

Paterson Institute for Cancer Research, Christie Hospital NHS Trust and Research Institute, Manchester